Reported about 13 hours ago
Weight-loss drug developer Metsera has disclosed a greater net loss of $156.26 million in its recent U.S. IPO filing, up from $34.18 million last year. Founded in 2022, the biotech firm is focusing on injectable and oral obesity treatments and plans to use IPO proceeds to fund clinical trials for its lead product, MET-097i. Metsera aims to capitalize on the booming weight-loss market projected to exceed $150 billion by the early 2030s.
Source: YAHOO